93 related articles for article (PubMed ID: 21810054)
1. Models and approaches for anti-TB drug testing.
Yasinskaya Y; Sacks L
Expert Rev Anti Infect Ther; 2011 Jul; 9(7):823-31. PubMed ID: 21810054
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Challenges and opportunities in developing novel drugs for TB.
Kaneko T; Cooper C; Mdluli K
Future Med Chem; 2011 Sep; 3(11):1373-400. PubMed ID: 21879843
[TBL] [Abstract][Full Text] [Related]
4. Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size.
de Steenwinkel JE; ten Kate MT; de Knegt GJ; Verbrugh HA; van Belkum A; Hernandez-Pando R; Bakker-Woudenberg IA
Int J Tuberc Lung Dis; 2011 Nov; 15(11):1478-84, i. PubMed ID: 22008760
[TBL] [Abstract][Full Text] [Related]
5. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
7. Anti-tuberculosis drug resistance among retreatment patients seen at St Peter Tuberculosis Specialized Hospital.
Meskel DW; Abate G; Lakew M; Goshu S; Aseffa A
Ethiop Med J; 2008 Jul; 46(3):219-25. PubMed ID: 19271385
[TBL] [Abstract][Full Text] [Related]
8. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
Cox HS; Niemann S; Ismailov G; Doshetov D; Orozco JD; Blok L; Rüsch-Gerdes S; Kebede Y
Clin Infect Dis; 2007 Jun; 44(11):1421-7. PubMed ID: 17479936
[TBL] [Abstract][Full Text] [Related]
9. Extensively drug-resistant tuberculosis: new strains, new challenges.
Banerjee R; Schecter GF; Flood J; Porco TC
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):713-24. PubMed ID: 18847407
[TBL] [Abstract][Full Text] [Related]
10. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
[TBL] [Abstract][Full Text] [Related]
11. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
Lienhardt C; Vernon A; Raviglione MC
Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
[TBL] [Abstract][Full Text] [Related]
13. Nature of drug resistance and predictors of multidrug-resistant tuberculosis among patients seen at the Philippine General Hospital, Manila, Philippines.
Mendoza MT; Gonzaga AJ; Roa C; Velmonte MA; Jorge M; Montoya JC; Tan Torres T; Ong M; Barez MY; Ang CF
Int J Tuberc Lung Dis; 1997 Feb; 1(1):59-63. PubMed ID: 9441060
[TBL] [Abstract][Full Text] [Related]
14. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina.
Palmero DJ; Ambroggi M; Brea A; De Lucas M; Fulgenzi A; Martínez D; Mosca C; Musella R; Natiello M; Gonzalez C; Abbate E
Int J Tuberc Lung Dis; 2004 Jun; 8(6):778-84. PubMed ID: 15182150
[TBL] [Abstract][Full Text] [Related]
15. The early bactericidal activity of anti-tuberculosis drugs: a literature review.
Donald PR; Diacon AH
Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S75-83. PubMed ID: 18762155
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Kam KM; Yip CW
Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
[TBL] [Abstract][Full Text] [Related]
17. Multidrug-resistant tuberculosis at Srinagarind Hospital, Khon Kaen, Thailand.
Reechaipichitkul W
Southeast Asian J Trop Med Public Health; 2002 Sep; 33(3):570-4. PubMed ID: 12693593
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of new antituberculosis drugs in mouse models.
Davies GR; Pym AS; Mitchison DA; Nuermberger EL; Grosset JH
Antimicrob Agents Chemother; 2007 Jan; 51(1):403; author reply 403-4. PubMed ID: 17182861
[No Abstract] [Full Text] [Related]
19. Tuberculosis drug development: progress, challenges, and the road ahead.
Ginsberg AM
Tuberculosis (Edinb); 2010 May; 90(3):162-7. PubMed ID: 20382086
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
